Vaisala Group
10.3.2021 13:46:48 CET | Globenewswire | Press release
Vaisala Corporation
Managers’ Transactions
March 10, 2021 at 2:45 p.m. (EET)
Vaisala Corporation: Managers’ Transactions - Lahtinen, Sampsa
Vaisala Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Lahtinen, Sampsa
Position: Other senior manager
Issuer: Vaisala Oyj
LEI: 743700RNDD7KU11HW873
Notification type: INITIAL NOTIFICATION
Reference number: 743700RNDD7KU11HW873_20210308155909_4
____________________________________________
Transaction date: 2021-03-10
Venue not applicable
Instrument type: SHARE
ISIN: FI0009900682
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION
Transaction details
(1): Volume: 8,864 Unit price:
Aggregated transactions
(1): Volume: 8,864 Volume weighted average price:
More information
Kaarina Muurinen, CFO
Tel. +358 40 577 5066
Distribution
Nasdaq Helsinki
Key media
vaisala.com
Vaisala is a global leader in environmental and industrial measurement. Building on over 80 years of experience, Vaisala provides observations for a better world. We are a reliable partner for customers around the world, offering a comprehensive range of innovative observation and measurement products and services. Headquartered in Finland, Vaisala employs over 1,900 professionals worldwide and is listed on the Nasdaq Helsinki stock exchange. vaisala.com twitter.com/VaisalaGroup
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Rocket Lab Corporation28.3.2026 11:39:53 CET | Press release
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
